Investors were pleased Thursday with Human Genome Sciences Inc.'s news that it had submitted its much-anticipated biologics license application (BLA) to the FDA for Benlysta (belimumab) as a treatment for systemic lupus erythematosus (SLE), pushing shares of the firm up 8.2 percent. (BioWorld Today) Read More
